Fuente: International Business Times
US President Donald Trump speaks during a meeting at the White House In one of the most sweeping health policy announcements of his second term, President Donald Trump has unveiled new agreements with pharmaceutical giants Novo Nordisk and Eli Lilly that significantly reduce the cost of blockbuster obesity drugs, including Wegovy, Ozempic, and Zepbound. Under the deal, announced Thursday, certain GLP-1 weight loss medications will be available for as little as $149 (approximately £114) per month, a sharp drop from the current average retail price of $1,000–$1,350 (approximately £762-1,029). The discounts will be offered through the federal government's upcoming TrumpRx platform, which launches in early 2026, according to reports.
